Mosunetuzumab (Lunsumio®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL) Update September 2022

Rothschedl, E. and Wolf, S. (2022): Mosunetuzumab (Lunsumio®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL) Update September 2022. Oncology Fact Sheet Nr. 92.

[thumbnail of Oncology Fact Sheet Nr.92_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
114kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Oncology Fact Sheet Nr. 92
Deposited on:	16 May 2022 10:20
Last Modified:	26 Sep 2022 12:05

Repository Staff Only: item control page